Combination Chemotherapy of Intermediate and High- Grade Non-Hodgkin's Lymphoma with ProMACE-CytaBOM

African americans treated on SWOG NHL studies: Similar incidence, received dose intensity and outcome to caucasian patients.

S Dahlberg;RI Fisher;CA Coltman ASCO 13:370(#1251)

Lack of outcome difference by beam energy in head and neck cancer patients treated with cobalt-60 and 4MV rather than 6MV photons.

JG Schwade;NC Farnan;A Ares;DE Schuller;MM Oken;TJ Ervin;C Jacobs;H Wheeler;G Laramore Proc of the American Radium Society 76th Annual Meeting :26-27(#43)

A predictive model for aggressive non-Hodgkin's lymphoma. THE INTERNATIONAL NON-HODGKIN'S LYMPHOMA PROGNOSTIC FACTORS PROJECT.

NEJM 329(14):987-994

Development of a predictive model for aggressive lymphoma. The International NHL prognostic factors project.

N Shipp;D Harrington;J Anderson;J Armitage;G Bonadonna;G Brittinger;F Cabanillas;G Canellas;R Coiffier;J Connors;R Cowan;C Crowther;M Engelhard;R Fisher;C Gisselbrecht;E Horning;E Lepage;A Lister;J Meerwaldt;E Montserrat;N Nissen;M Oken;B Peterson;C Tondini;W Valasquez;B Yeap ASCO 11:319(#1084)

Long term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.

RI Fisher;DL Long;VT DeVita;SM Hubbard;TP Miller;RC Young Ann Oncol 2(suppl.1):33-35

Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: A Groupwide Southwest Oncology Group study.

TP Miller;S Dahlberg;JK Weick;JC Files;HJ Eyre;KB Pendergrass;RI Fisher JCO 8(12):1951-1958

Dose intensity is not associated with subsequent survival after adjustment for known prognostic factors in non-Hodgkin's lymphoma patients treated with m-BACOD, ProMace-CytaBOM, and MACOP-B on Southwest Oncology Group study.

S Dahlberg;TP Miller;B Dana;J Weick;RI Fisher ASCO 9:225(#986)

The treatment of non-hodgkin's lymphoma with m-BACOB,ProMACE-CytaBOM, and MACOP-B: The Southwest Oncology Group (SWOG)experience.

J Weick;S Dahlberg;T Miller;B Dana;R Fisher ASCO 8:254(#990)

Southwest Oncology Group clinical trials for intermediate andhigh grade non-hodgkin's lymphomas.

TP Miller;BW Dana;JK Weick;SE Jones;C Coltman, Jr;S Dahlberg;RI Fisher;S Green;HI Pierce;RW Roach;SP Balcerzak;L Militello Sem Hematol 25(2):17-22

Southwest Oncology Group clinical trials for intermediate andhigh-grade non-hodgkin's lymphomas.

RI Fisher;TP Miller;BW Dana;SE Jones;S Dahlberg;C Coltman, Jr Seminars in Hematology 24(2):21-25

ProMACE-CytaBOM is active with acceptable toxicity in patientswith unfavorable non-hodgkin's lymphomas: a groupwide Southwest OncologyGroup study.

TP Miller;S Dahlberg;SE Jones;RI Fisher;C Coltman, Jr ASCO :#C-776